The packaging solution ready to meet growing demand for specialty drugs

There’s been a shift in global medicine, and its ripples continue to spread. New drug development in traditional markets has slowed, and specialty drugs – typically biologics used for conditions requiring complex treatment, such as cancer – will be the largest contributor to branded drug spending growth by 2017. In fact, specialty drug development is expected to increase by 30 percent over the next 5 years, outpacing most other medical spending, according to IMS Health.

This pivot affects packaging manufacturers, too. Biologics and other specialty drugs are usually produced in small batches, pushing manufacturers to be more agile and quickly change their production schedules for different products.

SCHOTT’s adaptiQ® can hold up to 100 sterile vials in a standard tub.

SCHOTT’s adaptiQ® can hold up to 100 sterile vials in a standard tub.

Reducing process complexity is one goal for these packaging experts, but quality control can’t be overlooked. These high-value drugs are expensive to produce, and even a one percent failure rate can lead to unprofitability. These factors have forced drug packaging manufacturers to rethink filling processes, and opened the door for ready-to-use (RTU) solutions. RTU concepts for syringes have been common practice for decades, but the concept has just recently been adapted for vials and cartridges.

The tricky challenges of new drug development and packaging

The journey of specialty drugs and biologics to the mainstream is littered with roadblocks and detours. In addition to the small margin for error, any unintended bioburden due to packaging failure increases the risk of drug contamination that can harm patients. Additionally, regulatory guidelines differ by country, and these rules sometimes prevent biologics from being sold, if manufacturing and filling is completed abroad.

Few pharma companies have already invested in small production facilities throughout the world to match demand while satisfying regulatory guidelines. But because these biologics and specialty drugs are high value and produced in small batches, many manufacturers are outsourcing the container and component processing to achieve higher efficiency without costly investment. Together, these two scenarios have raised the profile of RTU packaging.

Reducing risks in a high-stakes market

Developed as a form of risk reduction, RTU packaging grants manufacturers the ability to produce small to medium drug batches – biologics and specialty drug compounds in particular – without implementing wholesale changes to a manufacturing line. RTU packaging also preserves the sterility required by regulatory standards.

As the rules surrounding sterility for injectable drugs grow more complex, and as costs increase, many drug manufacturers are outsourcing the job of sterilizing and filling vials, syringes, and ampoules to their packaging partners. That lowers the total cost of ownership for manufacturers and boosts efficiency and safety as more RTU packaging is brought online.

The industry-standard nest and tub is one example of how RTU packaging for vials has evolved. Traditional vial packaging was a bit of a free-for-all, as vials were un-nested and moved freely through a packaging line. This movement of vials increased the risk of scratches and breakage.

But in new RTU solutions, such as SCHOTT’s adaptiQ®, vials are nested in the standard tub throughout the filling process, and come onto the line sterilized and primed for filling. The entire tub, which can hold up to 100 sterile vials, can be loaded onto production lines without reconfiguring or adjusting the mechanics of the system. This standardization allows packaging manufacturers to easily transition from large-scale production of a drug to a low-volume filling request – again, great for low-volume, high-cost drugs. Plus, the system can adjust to fill vials to specific volume based on the drug compound.

Ready for the trillion-dollar industry

Global spending on medicines will hit the trillion dollar mark by 2017. Spending on specialty pharmaceuticals will rise to $193 billion in developed nations, and $43 billion in pharmerging nations – developing countries where use of pharmaceuticals is quickly growing – over the next few years, IMS Health found.

That’s put the pressure on pharma packaging manufacturers to develop vials and syringes, and the method of processing, for these high-value drugs. The result is RTU packaging that ensures accurate and safe filling for biologics and specialty drugs.

As specialty drugs gain market share, RTU and other packing solutions will grow in importance to ensure drug safety and the long-term health of this growing segment of pharmaceuticals.

(4 Posts)

Hello, I’m Anil Busimi, Head of Global Product Management in SCHOTT’s syringe division. I joined SCHOTT in 2003, and have since held a number of different positions, including Business Development Manager for microarrays, Consultant in corporate strategy and development, and Strategic Business Manager for the global pharmaceutical packaging division. I was the Global Product Manager for SCHOTT’s TopPac syringes before taking on my current role. I hold a master’s degree in agriculture and genetics, as well as an MBA.

Leave a Reply

Your email address will not be published. Required fields are marked *

thirteen + 14 =